Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

TY - JOUR

T1 - Management of Patients with Advanced Prostate Cancer

T2 - The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

AU - Gillessen, Silke

AU - Attard, Gerhardt

AU - Beer, Tomasz M

AU - Beltran, Himisha

AU - Bossi, Alberto

AU - Bristow, Rob

AU - Carver, Brett

AU - Castellano, Daniel

AU - Chung, Byung Ha

AU - Clarke, Noel

AU - Daugaard, Gedske

AU - Davis, Ian D

AU - de Bono, Johann

AU - Borges Dos Reis, Rodolfo

AU - Drake, Charles G

AU - Eeles, Ros

AU - Efstathiou, Eleni

AU - Evans, Christopher P

AU - Fanti, Stefano

AU - Feng, Felix

AU - Fizazi, Karim

AU - Frydenberg, Mark

AU - Gleave, Martin

AU - Halabi, Susan

AU - Heidenreich, Axel

AU - Higano, Celestia S

AU - James, Nicolas

AU - Kantoff, Philip

AU - Kellokumpu-Lehtinen, Pirkko-Liisa

AU - Khauli, Raja B

AU - Kramer, Gero

AU - Logothetis, Chris

AU - Maluf, Fernando

AU - Morgans, Alicia K

AU - Morris, Michael J

AU - Mottet, Nicolas

AU - Murthy, Vedang

AU - Oh, William

AU - Ost, Piet

AU - Padhani, Anwar R

AU - Parker, Chris

AU - Pritchard, Colin C

AU - Roach, Mack

AU - Rubin, Mark A

AU - Ryan, Charles

AU - Saad, Fred

AU - Sartor, Oliver

AU - Scher, Howard

AU - Sella, Avishay

AU - Shore, Neal

AU - Smith, Matthew

AU - Soule, Howard

AU - Sternberg, Cora N

AU - Suzuki, Hiroyoshi

AU - Sweeney, Christopher

AU - Sydes, Matthew R.

AU - Tannock, Ian

AU - Tombal, Bertrand

AU - Valdagni, Riccardo

AU - Wiegel, Thomas

AU - Omlin, Aurelius

N1 - Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PY - 2018/2

Y1 - 2018/2

N2 - Background In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some of these topics. Objective To present the report of APCCC 2017. Design, setting, and participants Ten important areas of controversy in APC management were identified: high-risk localised and locally advanced prostate cancer; “oligometastatic” prostate cancer; castration-naïve and castration-resistant prostate cancer; the role of imaging in APC; osteoclast-targeted therapy; molecular characterisation of blood and tissue; genetic counselling/testing; side effects of systemic treatment(s); global access to prostate cancer drugs. A panel of 60 international prostate cancer experts developed the program and the consensus questions. Outcome measurements and statistical analysis The panel voted publicly but anonymously on 150 predefined questions, which have been developed following a modified Delphi process. Results and limitations Voting is based on panellist opinion, and thus is not based on a standard literature review or meta-analysis. The outcomes of the voting had varying degrees of support, as reflected in the wording of this article, as well as in the detailed voting results recorded in Supplementary data. Conclusions The presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available, including disease extent and location, prior therapies regardless of type, host factors including comorbidities, as well as patient preferences, current and emerging evidence, and logistical and economic constraints. Inclusion of men with APC in clinical trials should be strongly encouraged. Importantly, APCCC 2017 again identified important areas in need of trials specifically designed to address them. Patient summary The second Advanced Prostate Cancer Consensus Conference APCCC 2017 did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer. The aim of the conference is to bring the expertise of world experts to care givers around the world who see less patients with prostate cancer. The conference concluded with a discussion and voting of the expert panel on predefined consensus questions, targeting areas of primary clinical relevance. The results of these expert opinion votes are embedded in the clinical context of current treatment of men with advanced prostate cancer and provide a practical guide to clinicians to assist in the discussions with men with prostate cancer as part of a shared and multidisciplinary decision-making process. At the Advanced Prostate Cancer Consensus Conference, 10 important areas of controversy in advanced prostate cancer management were identified, discussed, and the experts voted on 150 predefined consensus questions. The full report of the results is summarised here.

AB - Background In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some of these topics. Objective To present the report of APCCC 2017. Design, setting, and participants Ten important areas of controversy in APC management were identified: high-risk localised and locally advanced prostate cancer; “oligometastatic” prostate cancer; castration-naïve and castration-resistant prostate cancer; the role of imaging in APC; osteoclast-targeted therapy; molecular characterisation of blood and tissue; genetic counselling/testing; side effects of systemic treatment(s); global access to prostate cancer drugs. A panel of 60 international prostate cancer experts developed the program and the consensus questions. Outcome measurements and statistical analysis The panel voted publicly but anonymously on 150 predefined questions, which have been developed following a modified Delphi process. Results and limitations Voting is based on panellist opinion, and thus is not based on a standard literature review or meta-analysis. The outcomes of the voting had varying degrees of support, as reflected in the wording of this article, as well as in the detailed voting results recorded in Supplementary data. Conclusions The presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available, including disease extent and location, prior therapies regardless of type, host factors including comorbidities, as well as patient preferences, current and emerging evidence, and logistical and economic constraints. Inclusion of men with APC in clinical trials should be strongly encouraged. Importantly, APCCC 2017 again identified important areas in need of trials specifically designed to address them. Patient summary The second Advanced Prostate Cancer Consensus Conference APCCC 2017 did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer. The aim of the conference is to bring the expertise of world experts to care givers around the world who see less patients with prostate cancer. The conference concluded with a discussion and voting of the expert panel on predefined consensus questions, targeting areas of primary clinical relevance. The results of these expert opinion votes are embedded in the clinical context of current treatment of men with advanced prostate cancer and provide a practical guide to clinicians to assist in the discussions with men with prostate cancer as part of a shared and multidisciplinary decision-making process. At the Advanced Prostate Cancer Consensus Conference, 10 important areas of controversy in advanced prostate cancer management were identified, discussed, and the experts voted on 150 predefined consensus questions. The full report of the results is summarised here.

U2 - 10.1016/j.eururo.2017.06.002

DO - 10.1016/j.eururo.2017.06.002

M3 - Journal article

C2 - 28655541

SN - 0302-2838

VL - 73

SP - 178

EP - 211

JO - European Urology

JF - European Urology

IS - 2

ER -